← Daily Brief
The Bell BriefFrom Dr. Jennifer Bell, DDS
MEDIUMClinicalTier 1

Authors’ Response

SourceJournal of the American Dental Association (JADA)Tier 1Peer-Reviewed Research

Originally at sciencedirect.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

JADA authors provide an evidence-based clarification on saliva-based oral-cancer biomarkers that could shape future chair-side screening protocols; practice owners and oral surgeons evaluating new diagnostic tools should note the authors’ updated performance data.

Key points

  • Letter published 28 July 2026 in JADA addresses accuracy of salivary HPV-16 and CA-125 assays for oral squamous-cell carcinoma.
  • Updated pooled sensitivity 82 % and specificity 79 % reported for early-stage lesions in 1,247 patients across two Australian cohorts.
  • Authors emphasize the assays are adjunctive and still require biopsy confirmation before definitive treatment planning.
  • No immediate billing codes or payer coverage changes mentioned; dentists considering capital purchases should await forthcoming clinical-utility trials.

Who should care

OwnerSpecialistAssociate

Read the original on Journal of the American Dental Association (JADA)

Full reporting and any paywall content live on sciencedirect.com. We summarize and score; we do not republish.

Open original

Related